Study of Pembrolizumab With Maintenance Olaparib or Maintenance Pemetrexed in First-line (1L) Metastatic Nonsquamous Non-Small-Cell Lung Cancer (NSCLC) (MK-7339-006, KEYLYNK-006)
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
Regeneron Pharmaceuticals
National Cancer Institute (NCI)
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
Hoffmann-La Roche
Children's Oncology Group
Hoffmann-La Roche
PrECOG, LLC.
Bristol-Myers Squibb
Radiation Therapy Oncology Group
Bristol-Myers Squibb
Shanghai Henlius Biotech
Incyte Corporation
Hoffmann-La Roche
Hoffmann-La Roche
Bristol-Myers Squibb
Merck Sharp & Dohme LLC
St. Jude Children's Research Hospital
American Regent, Inc.
Merck Sharp & Dohme LLC
AstraZeneca
Mario Negri Institute for Pharmacological Research
Spanish Lung Cancer Group
BeiGene
Hoffmann-La Roche
AbbVie
BeiGene
EMD Serono
Novartis
Samsung Bioepis Co., Ltd.
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
Hoffmann-La Roche
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
Grupo Español de Investigación en Cáncer de Ovario
G1 Therapeutics, Inc.
AstraZeneca
Women's Cancer Care Associates, LLC
Hoffmann-La Roche
Hoffmann-La Roche
Jiangsu Simcere Pharmaceutical Co., Ltd.
Merck Sharp & Dohme LLC
Bristol-Myers Squibb
Ono Pharmaceutical Co. Ltd